Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.31 |
| ▸ | F11 | P03951 | 2/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2209141 | 0.81 | UCHL1 (0.34) | FFAR1F2F11PRSS1PRSS2 | |
| SCHEMBL482176 | 0.80 | FFAR1 (0.36) | FFAR1F2F11PRSS1PRSS2 | |
| SCHEMBL28809235 | 0.76 | USP30 (0.33) | FFAR1 | |
| SCHEMBL20574237 | 0.74 | USP30 (0.37) | FFAR1F2F11PRSS1PRSS2 | |
| SCHEMBL29267550 | 0.74 | FFAR1 (0.40) | FFAR1 | |
| SCHEMBL29267551 | 0.72 | FFAR1 (0.34) | FFAR1 | |
| SCHEMBL31220431 | 0.71 | NPC1 (0.34) | FFAR1 | |
| SCHEMBL28879574 | 0.71 | NPC1 (0.36) | FFAR1 | |
| SCHEMBL29266029 | 0.70 | KDM4E (0.33) | — | |
| SCHEMBL32684434 | 0.69 | USP30 (0.36) | FFAR1DGAT1UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
| EP-4059928-A1 | ROCK INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2022-09-21 | — | — | EP | disclosed |
| US-20220235042-A1 | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors | CHILDREN'S HOSPITAL MEDICAL CENTER | 2022-07-28 | — | — | US | disclosed |
| WO-2021093795-A1 | ROCK INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉朗来科技发展有限公司 | 2021-05-20 | — | — | WO | disclosed |
| EP-3288936-B1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-06 | — | — | EP | disclosed |
| US-10611730-B2 | Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-07 | — | — | US | disclosed |
| US-20190092735-A1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-28 | — | — | US | disclosed |
| EP-3227286-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINES AND IMIDAZO[1,2-A]PYRAZINES AND THEIR USE | Bayer Pharma AG (DE) | 2018-12-26 | — | — | EP | disclosed |
| EP-3227286-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINES AND IMIDAZO[1,2-A]PYRAZINES AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2017-10-11 | — | — | EP | disclosed |
| US-9745311-B2 | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors | INCYTE CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9206128-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
| US-20140288123-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| EP-2780014-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| WO-2014026125-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2014-02-13 | — | — | WO | disclosed |
| US-20140045814-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2013075083-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-05-23 | — | — | WO | disclosed |
| EP-2593447-A2 | NEW HETEROCYCLIC COMPOUNDS AS PESTICIDES | Bayer Intellectual Property GmbH (DE) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007500-A2 | NEW HETEROCYCLIC COMPOUNDS AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2012-01-19 | — | — | WO | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | FFAR1 838/4885F2 107/4885F11 958/4885 |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | FFAR1 2647/4885F2 520/4885F11 1640/4885 |
| US-20220235042-A1 | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors | IRAK1, IRAK4, IRAK2 | FFAR1 1443/4885F2 3230/4885F11 1785/4885 |
| US-20140288123-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | FFAR1 4565/4885F2 4820/4885F11 4629/4885 |
| US-10611730-B2 | Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators | GRIN1, GABRE, GRIN3A | FFAR1 113/4885F2 4415/4885F11 3252/4885 |
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROCK1, CYP11B1, CYP4A11 | FFAR1 269/4885F2 1040/4885F11 319/4885 |
| US-20190092735-A1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GABRE, GRIN3A | FFAR1 113/4885F2 4415/4885F11 3252/4885 |
| US-20140045814-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | FGFR1, FGFR2, FGFR3 | FFAR1 1156/4885F2 1079/4885F11 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.